Genelux Corporation CEO, Dr. Aladar A. Szalay, To Give A Keynote Lecture At The 8th International Conference On Oncolytic Virus Therapeutics

SAN DIEGO, CA--(Marketwired - April 08, 2014) -

Genelux Corporation, a clinical-stage biopharmaceutical company developing vaccinia virus-based cancer therapies and diagnostics, today announced that its Founder and CEO, Dr. Aladar A. Szalay, a respected researcher and thought leader in the field of oncolytic virotherapy and immunotherapy, will give a keynote lecture at the 8th International Conference on Oncolytic Virus Therapeutics in Oxford, England from April 13 through 15, 2014. The annual meeting brings together the world’s leading researchers and clinicians from the preeminent cancer centers, universities, and biotech and pharma companies investigating the use of oncolytic viruses for cancer diagnostics and therapeutics. Genelux will also present an abstract at the conference -- Diagnosis and therapy of cancer with Vaccinia: from preclinical research to human clinical trials.

“It is both an exciting and challenging time for the field, particularly as we now have several different viruses with demonstrated clinical relevance. In many ways we are only beginning to understand the complex interactions between oncolytic viruses in human cancer biology and immunology, and how this relates to drug development, clinical trial design and dosing and outcome measures,” says Dr. Szalay. “The promise held by oncolytic viruses is immense, and I believe in the next several years we will see more and more success as developers harness their full therapeutic potential against a number of human and also veterinary cancers.”

About Genelux Corporation
Headquartered in San Diego, California, Genelux Corporation is a privately held, clinical stage biopharmaceutical company dedicated to fundamentally changing the way in which cancer is diagnosed and treated. The company has developed a proprietary oncolytic vaccinia virus-based technology platform that can be engineered to insert specific therapeutic genes for delivery and amplification of anti-cancer proteins and RNAs into cancer cells without harming healthy cells. This platform includes a green fluorescent protein (GFP) as a bioluminescent diagnostic. The company is also incorporating advanced diagnostic deep-tissue imaging technologies into its viral platform to enable highly specific visualization of tumors and circulating cancer cells. GL-ONC1, the company’s lead oncology product candidate, is an attenuated vaccinia virus (Lister strain) that is currently under evaluation in multiple human clinical trials in the US and Europe. For more information please visit http://www.genelux.com/

Genelux Forward Looking Statement
Statements made about Genelux Corporation, other than statements of historical fact, reflect Management’s current beliefs and assumptions founded on the data and information currently available to us. Statements of the company’s progress, results, timing of pre-clinical and clinical trials and projections for product pipelines are examples of forward-looking statements. By definition, such undertakings involve risks, uncertainties and assumptions, and are subject to a number of such factors that could cause actual results to differ substantially from statements made, including but not limited to: risks associated with the success of clinical trials, research and development programs, regulatory approval processes for clinical trials, competitive technologies and products, patents, inception and/or continuation of corporate and other strategic partnerships and the need for additional funding or financing.

Digg this Bookmark with del.icio.us Add to Newsvine

Technorati: biotechnology pharmaceutical cancer finance